Guidelines for diagnosing and treating pulmonary infiltrates in children with acute leukaemia: impact of timely decisions

Acta Paediatrica
M E Y FuruyaG Zúñiga-Vázquez


Children with leukaemia are at increased risk of pulmonary complications, often with unspecific clinical data, delayed diagnosis and a high mortality rate. We evaluated the usefulness of diagnostic-therapeutic guidelines (DTG) in which specific times for decision making were incorporated. Clinical charts of children with acute leukaemia and suspicion of pulmonary involvement were reviewed. Patients were allocated to group I if their diagnostic and therapeutic decisions were in accordance with the DTG, and to group II if not. Children from group I (n=32) and group II (n=28) did not differ with respect to age (9.3+/-0.5 years old, mean+/-SEM), gender, type, risk and stage of leukaemia, anaemia and neutropenia. Total length of hospital stay and hospitalization due to the pulmonary disease were shorter in group I than in group II (14.8+/-2.1 vs. 28.5+/-3.7 days, p=0.0016; and 10.8+/-1.0 vs. 18.4+/-1.8 days, p=0.0003, respectively). Two patients (6.3%) died due to the pulmonary pathology in group I, and nine (32.1%, p=0.016) in group II. Diagnostic-therapeutic guidelines that incorporate timely decisions constitute a useful algorithm to reduce the length of hospital stay and mortality in children with acute leukaemia and pulmonary i...Continue Reading


Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H RexJ E Edwards
Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D A StevensG A Pankey
Jul 13, 2001·Infectious Disease Clinics of North America·B A Cunha
Aug 30, 2001·Critical Care Clinics·A Safdar, D Armstrong
Nov 9, 2001·Radiologic Clinics of North America·M P HiornsN L Müller
Feb 19, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Walter T HughesLowell S Young
May 15, 2002·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Miranda VerschraagenWim J F van der Vijgh
Apr 15, 2003·Leukemia & Lymphoma·Giorgina SpecchiaVincenzo Liso
Jun 10, 2003·Emergency Medicine Clinics of North America·Walter G Belleza, Brian Browne
Jul 10, 2003·The Journal of Infection·F RoblotB Becq-Giraudon
Nov 20, 2004·Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology·Minoru Yoshida
Jul 13, 2005·Pediatric Clinics of North America·Thomas J Sandora, Marvin B Harper
Nov 4, 2005·Seminars in Respiratory and Critical Care Medicine·Corrado Girmenia, Pietro Martino
Jun 5, 2007·The Journal of Antimicrobial Chemotherapy·R MastertonP Davey


Feb 11, 2012·Journal of Pediatric Hematology/oncology·M E Y FuruyaAlicia Rodríguez-Velasco
Jan 7, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·DeepakBabu ChellapandianLillian Sung

Related Concepts

Lung Diseases
Acute Myeloid Leukemia, M1
Leukemia, Lymphocytic, Acute, L2
Cessation of Life
Decision Making

Related Feeds


Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
Raymundo Rodríguez-MoctezumaJuan Manuel López-Carmona
Ceská a slovenská oftalmologie : casopis Ceské oftalmologické spolecnosti a Slovenské oftalmologické spolecnosti
E RíhováJ Sach
© 2021 Meta ULC. All rights reserved